These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 5134893

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Unilateral adrenal hypersecretion of both aldosterone and cortisol in two first cousins with a syndrome of mineralocorticoid excess but without signs of hypercortisolism.
    Ferri C, Falaschi P, Gualdi G, Coassin S, Carlomagno A, De Siati L, Bonavita MS, Balsano F.
    Endocr Res; 1994 May; 20(2):165-92. PubMed ID: 8055832
    [Abstract] [Full Text] [Related]

  • 23. Effects of an aldosterone antagonist, spironolactone, on pinealectomized rats.
    Karppanen H, Vapaatalo H.
    Pharmacology; 1971 May; 6(5):257-64. PubMed ID: 5143207
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The diagnostic and therapeutic value of spironolactone in patients with systemic hypertension.
    Burden RP, Booth LJ, Aber GM.
    Nephron; 1973 May; 9(3):171-88. PubMed ID: 4682245
    [No Abstract] [Full Text] [Related]

  • 27. [A case of apparent mineralocorticoid excess caused by type 2 11 beta- hydroxysteroid dehydrogenase deficiency].
    Morineau G, Pascoe L, Marc JM, Caillette A, Krozowski Z, Corvol P, Fiet J.
    Arch Mal Coeur Vaiss; 1997 Aug; 90(8):1111-5. PubMed ID: 9404418
    [Abstract] [Full Text] [Related]

  • 28. Role of glucocorticoid in the development of glycyrrhizin-induced hypertension.
    Kageyama Y, Suzuki H, Saruta T.
    Clin Exp Hypertens; 1994 Nov; 16(6):761-78. PubMed ID: 7858558
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Diuretic therapies in low renin and normal renin essential hypertension.
    Brooks CS, Johnson CA, Kotchen JM, Kotchen TA.
    Clin Pharmacol Ther; 1977 Jul; 22(1):14-20. PubMed ID: 326459
    [Abstract] [Full Text] [Related]

  • 32. Apparent mineralocorticoid excess syndrome: report of one family with three affected children.
    Al-Harbi T, Al-Shaikh A.
    J Pediatr Endocrinol Metab; 2012 Jul; 25(11-12):1083-8. PubMed ID: 23329753
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Role of the adrenal cortex in hypertension.
    Liddle GW, Carey RM, Douglas JG.
    South Med J; 1973 Jan; 66(1):51-4. PubMed ID: 4683735
    [No Abstract] [Full Text] [Related]

  • 37. Renin activity, sodium and potassium in hypertensive patients.
    Overturf M, Fitz A, McBride J.
    J Chronic Dis; 1972 Nov; 25(10):621-34. PubMed ID: 4647222
    [No Abstract] [Full Text] [Related]

  • 38. Spironolactone as a nonspecific treatment for primary aldosteronism.
    Bravo EL, Dustan HP, Tarazi RC.
    Circulation; 1973 Sep; 48(3):491-8. PubMed ID: 4726231
    [No Abstract] [Full Text] [Related]

  • 39. Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.
    Vaughan ED, Laragh JH, Gavras I, Bühler FR, Gavras H, Brunner HR, Baer L.
    Am J Cardiol; 1973 Sep 20; 32(4):523-32. PubMed ID: 4729722
    [No Abstract] [Full Text] [Related]

  • 40. Treatment of low-renin essential hypertension. Comparison of spironolactone and a hydrochlorothiazide-triamterene combination.
    Douglas JG, Hollifield JW, Liddle GW.
    JAMA; 1974 Feb 04; 227(5):518-21. PubMed ID: 4589187
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.